CN107405369A8 - 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法 - Google Patents

包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法 Download PDF

Info

Publication number
CN107405369A8
CN107405369A8 CN201680005423.XA CN201680005423A CN107405369A8 CN 107405369 A8 CN107405369 A8 CN 107405369A8 CN 201680005423 A CN201680005423 A CN 201680005423A CN 107405369 A8 CN107405369 A8 CN 107405369A8
Authority
CN
China
Prior art keywords
diseases
butyrate
prevent
bacterium
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680005423.XA
Other languages
English (en)
Other versions
CN107405369A (zh
Inventor
威廉·迈德特·德·沃斯
蒂·蓬·纳姆·布伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wageningen Universiteit
Original Assignee
Wageningen Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wageningen Universiteit filed Critical Wageningen Universiteit
Publication of CN107405369A publication Critical patent/CN107405369A/zh
Publication of CN107405369A8 publication Critical patent/CN107405369A8/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及能够将L-赖氨酸转化为丁酸盐和/或将果糖-赖氨酸转化为丁酸盐的新的人肠分离株。该新分离株可用作益生菌或补充剂以促进胃肠道中丁酸盐的产生，从而预防和/或治疗受益于丁酸盐产生的病症或疾病。此外，该分离株可以预防和/或治疗由胃肠道中致病菌过量引起的且由L-赖氨酸或果糖-赖氨酸或其他晚期糖基化终产物介导的病症或疾病。
CN201680005423.XA 2015-01-09 2016-01-08 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法 Pending CN107405369A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15150701.9 2015-01-09
EP15150701 2015-01-09
PCT/EP2016/050310 WO2016110585A1 (en) 2015-01-09 2016-01-08 Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases

Publications (2)

Publication Number Publication Date
CN107405369A CN107405369A (zh) 2017-11-28
CN107405369A8 true CN107405369A8 (zh) 2018-01-16

Family

ID=52434520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680005423.XA Pending CN107405369A (zh) 2015-01-09 2016-01-08 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法

Country Status (13)

Country Link
US (2) US11452746B2 (zh)
EP (1) EP3242957B1 (zh)
KR (1) KR20170103920A (zh)
CN (1) CN107405369A (zh)
AU (1) AU2016205975B2 (zh)
BR (1) BR112017014649A2 (zh)
CA (1) CA2973285C (zh)
DK (1) DK3242957T3 (zh)
ES (1) ES2796355T3 (zh)
PL (1) PL3242957T3 (zh)
RU (1) RU2017126666A (zh)
SG (1) SG11201705450SA (zh)
WO (1) WO2016110585A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
KR20170103920A (ko) 2015-01-09 2017-09-13 바게닝겐 유니버시테이트 위장관, 대사성 및/또는 기타 질환의 치료 및/또는 예방을 위한 박테리아-함유 조성물 및 이의 사용 방법
EP3419637B1 (en) 2016-02-25 2021-01-27 Caelus Pharmaceuticals B.V. Compositions and methods for preventing and/or treating vitamin b12 deficiency
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
US11850270B2 (en) 2017-12-04 2023-12-26 The BioCollective, LLC Probiotics and methods of use
FR3085963A1 (fr) * 2018-09-19 2020-03-20 Novolyze Composition seche de microorganismes modeles
NL2024569B1 (en) * 2019-12-24 2021-09-06 Univ Wageningen Bacterium comprising myo-inositol to propionate pathway
RU2734718C1 (ru) * 2019-12-31 2020-10-22 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Способ уменьшения выраженности немоторных симптомов у пациентов, страдающих болезнью Паркинсона
NL2028324B1 (en) 2021-05-28 2022-12-12 Caelus Pharmaceuticals B V Insulin-sensitizing agent and butyrate-producing bacterium
WO2023121955A1 (en) * 2021-12-20 2023-06-29 Tainnovation Inc. The methods of and compositions for treating obesity, obesity-related diseases or cancers using a n6-methyllysine/l-lysine mixture

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006070891A1 (ja) * 2004-12-28 2006-07-06 Meiji Seika Kaisha, Ltd. 宿主に対して抗病性を付与する新規な菌株および菌体組成物
RU2613322C2 (ru) 2011-08-30 2017-03-15 Академис Медис Сентрум Способ профилактики и/или лечения инсулинорезистентности
US20140242654A1 (en) 2013-02-26 2014-08-28 Coskata, Inc. Butyrate Producing Clostridium species, Clostridium pharus
US9669059B2 (en) 2013-03-15 2017-06-06 University Of Florida Research Foundation, Incorporated Butyrogenic bacteria as probiotics to treat clostridium difficile
KR20170103920A (ko) 2015-01-09 2017-09-13 바게닝겐 유니버시테이트 위장관, 대사성 및/또는 기타 질환의 치료 및/또는 예방을 위한 박테리아-함유 조성물 및 이의 사용 방법

Also Published As

Publication number Publication date
AU2016205975B2 (en) 2021-05-27
US20180353552A1 (en) 2018-12-13
CA2973285C (en) 2023-10-17
RU2017126666A3 (zh) 2019-07-24
BR112017014649A2 (pt) 2018-03-13
SG11201705450SA (en) 2017-07-28
RU2017126666A (ru) 2019-02-12
CN107405369A (zh) 2017-11-28
PL3242957T3 (pl) 2020-10-05
EP3242957B1 (en) 2020-03-11
US20210069263A1 (en) 2021-03-11
CA2973285A1 (en) 2016-07-14
DK3242957T3 (da) 2020-06-02
US11426436B2 (en) 2022-08-30
US11452746B2 (en) 2022-09-27
WO2016110585A1 (en) 2016-07-14
EP3242957A1 (en) 2017-11-15
KR20170103920A (ko) 2017-09-13
ES2796355T3 (es) 2020-11-26
AU2016205975A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
CN107405369A8 (zh) 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法
MY186217A (en) Mixture of hmos
PH12015500106B1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
SE1550189A1 (en) Therapeutic and prophylactic composition produced by microbiota
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
EA201800564A1 (ru) Штамм akkermansia glycaniphilus, композиция, содержащая штамм, применение штамма и композиции, способ повышения уровня штамма akkermansia glycaniphilus в желудочно-кишечном тракте
MX2021016034A (es) Composiciones y métodos de tratamiento de una afección mediada por th2 usando prevotella.
EA201992176A1 (ru) Пробиотические молекулы для снижения вирулентности патогена
MX2012013834A (es) Cepas probioticas para mejorar el sistema nervioso enterico.
MY179105A (en) Methods of treating alzheimer's disease
MX2017016283A (es) Lactobacillus paracasei para la produccion de acido linoleico conjugado, preparaciones nutricionales y farmaceuticas que lo contienen y sus usos.
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
MX2018008644A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
UA118339C2 (uk) Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
AU2017261919A1 (en) Fat and medical uses thereof
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
MX2019000677A (es) Células miméticas de células b.
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2020001501A (es) Streptococcus australis como bioterapeuticos.
WO2015187638A3 (en) Method of reducing e. coli or salmonella contamination of agricultural products

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application

Correction item: Classification number

Correct: A61K 35/741(2015.01)|A23C 9/12(2006.01)|A61P 1/00(2006.01)|A61P 35/00(2006.01)|A61P 1/04(2006.01)|A61P 1/12(2006.01)|A61P 1/10(2006.01)|A61P 13/02(2006.01)|A61P 3/00(2006.01)|A61P 37/08(2006.01)|A61P 5/50(2006.01)|A61P 3/10(2006.01)|A61P 3/04(2006.01)|A61P 9/00(2006.01)|A61P 15/08(2006.01)|A61P 25/28(2006.01)|C12R 1/01(2006.01)

False: A99Z 99/00(2006.01)

Number: 48-01

Page: The title page

Volume: 33

CI02 Correction of invention patent application
RJ01 Rejection of invention patent application after publication

Application publication date: 20171128

RJ01 Rejection of invention patent application after publication